AnalystsSteve BrozakSteve Brozak's Stock Forecasts
AnalystsSteve Brozak
Sectors:
Analyst Ranking
Top 26%
#1330 out of 5134 analysts
Average Return
+22.75%
Win Rate
38%6 out of 16
Risk vs Reward
Poor
Good
Steve Brozak's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Cidara Therapeutics IncCDTX | +390.23% | $44.95 | $220.36 | 2025-06-23 - 2025-12-05 | Strong Buy |
Cidara Therapeutics IncCDTX | +191.98% | $75.47 | $220.36 | 2025-09-22 - 2025-12-05 | Strong Buy |
Cidara Therapeutics IncCDTX | +148.77% | $88.58 | $220.36 | 2025-09-24 - 2025-12-05 | Strong Buy |
Cidara Therapeutics IncCDTX | +98.95% | $110.76 | $220.36 | 2025-10-09 - 2025-12-05 | Strong Buy |
Marker Therapeutics IncMRKR | +15.79% | $1.14 | $1.32 | 2025-04-01 - 2025-12-05 | Strong Buy |
Steve Brozak Analyst Color
Get additional color on Steve Brozak's coverage of popular stocks
Steve Brozak's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Omeros CorpOMER | 2 | Strong Buy | $45.00 | +314.75% | Reiterates | 2 months ago |
Cidara Therapeutics IncCDTX | 5 | Strong Buy | $199.00 | -9.69% | Maintains | 2 months ago |
Celularity IncCELU | 2 | Buy | $6.00 | +203.03% | Upgrades | 3 months ago |
Marker Therapeutics IncMRKR | 1 | Strong Buy | $12.50 | +846.97% | Reiterates | 8 months ago |
Contrafect CorpCFRXQ | 2 | Strong Buy | $560.00 | N/A | Upgrades | 3 years ago |
Paratek Pharmaceuticals IncPRTK | 1 | Strong Buy | $11.00 | N/A | Upgrades | 4 years ago |
Redhill Biopharma LtdRDHL | 2 | Buy | $16,000.00 | N/A | Downgrades | 5 years ago |
Cohbar IncCWBR | 1 | Buy | $135.00 | N/A | Initiates Coverage On | 5 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.